Completion Date: 09/2017
Target: ADC Biotechnology
Deal Value: Undisclosed
Details: HMT LLP, led by partner Paul Read advised Maven
Capital Partners on its investment in anti-cancer drugs
manufacturer ADC Biotechnology
Funding: Maven Capital Partners
Financial Due Diligence: HMT
Buckinghamshire tech company Halma has acquired transport safety firm MK Test Systems Limited. Headquartered in…
BRiCS Development has secured an £11.55 million finance facility with Paragon Bank’s Development Finance team…
IT services and solutions company Mintivo has appointed Alex Jukes as its new Managing Director…
Bartlett Tree Experts have announced its intention to build a new arboretum and research facility…
The creation of a first-of-its-kind imaging system at the University of Surrey could help the…
Open Sight, which provides support across Hampshire to those living with or at risk of…